U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals (VNDA.O)  to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva (TEVA.TA) and Apotex.